Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stahl, S. M.
Right arrow Articles by Berger, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stahl, S. M.
Right arrow Articles by Berger, P. A.
NEUROLOGY 1982;32:889
© 1982 American Academy of Neurology

Bromocriptine, physostigmine, and neurotransmitter mechanisms in the dystonias

Stephen M. Stahl, M.D., Ph.D. and Philip A. Berger, M.D.

Mental Health Clinical Research Center, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, and the Schizophrenia Biologic Research Center, Veterans Administration Medical Center, Palo Alto, CA.

We studied eight patients with different types of dystonia by administering agonists and antagonists of acetylcholine (ACh) and dopamine (DA). In all seven patients who received physostigmine, there was an exacerbation of the dystonia. All six patients who received anticholinergic agents improved, as did five of eight who received bromocriptine. Neuroleptics worsened symptoms in four patients with generalized dystonia and improved symptoms in one patient with Meige syndrome. Our results suggest that DA-ACh imbalance may underlie the pathophysiology of dystonia in some patients and that bromocriptine may be effective in treating these patients.

Address correspondence and reprint requests to Dr. Stahl, Mental Health Clinical Research Center, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305.

This research was supported by a Barbra Streisand Fellowship for Dystonia Research from the Dystonia Medical Research Foundation, by the Medical Research Service of the Veterans Administration, by NIMH Specialized Research Center Grant No. MH 30854, by NIH General Clinical Research Center Grant No. RR70, and by the Veterans Administration Schizophrenia Biologic Research Center.

Accepted for publication January 7, 1982.




This article has been cited by other articles:


Home page
Arch NeurolHome page
W. A. Maltese, S. Bressman, S. Fahn, and D. C. De Vivo
Acetylcholinesterase Activity in Patients With Torsion Dystonia: Measurement in Erythrocyte Membranes
Arch Neurol, February 1, 1985; 42(2): 154 - 155.
[Abstract] [PDF]


Home page
Arch NeurolHome page
S. M. Stahl, K. F. Faull, J. D. Barchas, and P. A. Berger
CSF Monoamine Metabolites in Movement Disorders and Normal Aging
Arch Neurol, February 1, 1985; 42(2): 166 - 169.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1982 by AAN Enterprises, Inc.